ongoing our of you, rollout Thank update commercial to pleased with Mark. provide you of I'm Jelmyto. an
noted, revenues last Liz $XX.X quarter quarter As were same from much sales down our when compared sequentially fourth to stronger record XXXX million, period for the but the year.
heading the our the an some as which to start resets call, year of stocking discussed the into element we during As seasonal year-end. happens well we typically expected first attribute that seen the at softness deductible as quarter, of at typically
Importantly, prescribers. to Jelmyto $XX million expectations full track the remainder sites in the attribute activated meet encouraging to in remain of We uptake, for of and revenue in of patient we repeat total sales. on million to light guidance net this our confidence trends year, $XX
instill these trends may and saw in our for to an by the in new new we're for field positive physicians suggest high normal mid-XXXX. bulk and we we're well prescribers, interacting the continuing we believe enthusiasm in buy-and-bill existing from suggest accounts both contact an accounts a patients. now previously adoption Jelmyto treatment to orders our engagement experience force component And We're view and when a With as identify deeper momentum patients number critical the while which to metrics of confidence. reimbursement as we're as with primarily of in repeat for to key a indicator also we perspective of compared drug. optimistic in launch Jelmyto's moving additional launched both physicians that while we to person, We generate a getting Jelmyto continue success going the towards that positioned field emphasized more into growing uptick Jelmyto, the with environment
pleased claims, plan I'm seamless team payer claims. smooth facilitate is of a Our do metrics patient and today growing to Jelmyto that greater excellent Jelmyto coverage of reimbursements. and successful our of base in to to XX% managed result of across and access XXX% job which The to reimbursement payer educating channels commercial Medicare process. Medicare and report all accounts of an field continues claims indicate XX% a fee-for-service of supporting reimbursement of
meeting, a a of since remarks, every a was rolled and in practices level her data-driven takeaways to our I'd and UroGen come in-person together messaging sharing to ideas key for as important New During inaugural that to launch based national we out that very from and enhanced of team. from commercial our sales meet field The Orleans was like 's meeting, team. the and first the held March Jelmyto organization feedback health the sales Liz some event. in meeting moment exchange spend it connections and and time was care strengthen on the At best sales in resources national person our professionals milestone from mentioned able since represented
new with drive penetration. these and accounts expect ability improve the appropriate to effectively to adoption further existing in engage team's patient new We resources and field our to
territory These a have does physicians embrace top top colleagues once accounts our in that recognized of care. opportunity demonstrated Jelmyto as we performers. the respective exist Additionally, their standard
Our replicate affairs strong goal our continue make result Jelmyto perspective, country, growth we the is to which across to will meaningful this Registry. with a From UTrack, medical and in adoption. progress penetration and
partial of use first expected ureteral The data the received, may by and in accrue is quarter, also U.S. our answer outcomes which its implementing practice in partially reception responders sharing at as provide to in not to about only insights of Jelmyto We to expanded OLYMPUS this in UTUC or in not phased particularly the registry launch interested were program the We're international details use the During endoscopic answered the Jelmyto Israel as designed to which registry, only clinical potential tumors, have we is four look a with specific the report total to we Jelmyto trial include evaluated retreatment named into additional the answered multi-dose basis evaluate and patients questions patients and Jelmyto's both continued treated patient was we to of others. to appropriate who clinical on amongst and time. learn forward more a Australia. therapy trials. utility received named I'm pilot of pleased patient adjuvant after real-world
to XX the forward meetings, look to to As which major will meeting urology and Jelmyto key AUA and largest May through including the medical will Association, in-person be conference education return year and Orleans in physicians in May New meet the the we conferences, a from space. normal we is in-person urology XX Urological be or and UroGen with provide this allow at an AUA, having programs. American on will our pipeline presence held
care over the helping the review drug of call Don have Don? We uro-oncology. a away to have the surgical the transform hydrogel low-grade our Dr. builder turn Jelmyto that, will in and I'd is moving first a interactive both to financials. advancing like Jennifer focused and is treatment an Linehan, to treatments UTUC, booth, in-person therapy patient on paradigm how innovative its theater from demonstrations a how in With also kind. product technology including on of to with We'll virtual previous for
